Steffens Nadine Arnold, Petreceli Rodrigo Redel, Azevedo Victor Coden, França Adriana Streher, Hahn Roberta Zilles, Bondan Amanda Pacheco, Linden Rafael, Charão Mariele Feiffer, Schwarzbold Alexandre de Vargas, Brucker Natália
Graduate Program in Pharmaceutical Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil.
Biolab Clinical Analysis Laboratory, Santa Maria, RS, Brazil.
Clin Biochem. 2025 Mar;136:110874. doi: 10.1016/j.clinbiochem.2025.110874. Epub 2025 Jan 4.
Healthcare systems face several challenges, with microbial infections being one of the main concerns. Therapeutic drug monitoring (TDM) is a strategy that has been encouraged to optimize antimicrobial regimens, particularly those with significant toxicity and narrow therapeutic indices, such as amikacin (AMK). We aimed to evaluate AMK concentrations of patients in a non-routine TDM setting and compare the performance of immunoassay and chromatography methods for routine clinical use.
In this prospective study, peak (C) and trough (C) plasma samples were collected from 39 adult patients and quantified by ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS/MS). Relevant clinical information was collected from medical records. AMK concentrations and clinical data were analyzed to evaluate therapy performance and influencing factors. In addition, fluorescence polarized immunoassay (FPIA) and UPLC-MS/MS were compared with Passing-Bablok regression and Bland-Altman plot analysis.
AMK concentrations varied widely, with a median C of 41.40 µg/mL (interquartile range [IQR] 27.60 - 56.75 µg/mL) and a median C of 1.87 µg/mL (IQR 0.7 - 6.19 µg/mL). A high proportion of patients (83.1 %) failed to achieve the C therapeutic target, while 31.7 % failed to achieve the C therapeutic target. Overall, elderly patients and those with reduced renal function had higher C target attainment, while the same groups had lower C target attainment. The method comparison showed a mean difference of 1.54 % (limits of agreement -42.46 % to 45.54 %) in measured concentrations, with good correlation and no constant or proportional differences.
Many patients failed to reach the C target and were at risk of treatment failure, although adequate C was achieved more often. TDM with dose adjustments could improve AMK therapy, but further research is needed.
医疗保健系统面临诸多挑战,微生物感染是主要问题之一。治疗药物监测(TDM)是一种被鼓励用于优化抗菌治疗方案的策略,特别是对于那些具有显著毒性和窄治疗指数的药物,如阿米卡星(AMK)。我们旨在评估非常规TDM环境下患者的AMK浓度,并比较免疫测定法和色谱法在常规临床应用中的性能。
在这项前瞻性研究中,收集了39例成年患者的血浆峰浓度(C)和谷浓度(C)样本,并通过超高效液相色谱-质谱联用(UPLC-MS/MS)进行定量。从医疗记录中收集相关临床信息。分析AMK浓度和临床数据以评估治疗效果和影响因素。此外,通过Passing-Bablok回归和Bland-Altman图分析比较了荧光偏振免疫测定法(FPIA)和UPLC-MS/MS。
AMK浓度差异很大,C的中位数为41.40μg/mL(四分位数间距[IQR]为27.60 - 56.75μg/mL),C的中位数为1.87μg/mL(IQR为0.7 - 6.19μg/mL)。高比例患者(83.1%)未达到C治疗目标,而31.7%未达到C治疗目标。总体而言,老年患者和肾功能减退患者的C目标达成率较高,而同一组患者的C目标达成率较低。方法比较显示,测量浓度的平均差异为1.54%(一致性界限为-42.46%至45.54%),具有良好的相关性,且无恒定或比例差异。
许多患者未达到C目标,存在治疗失败的风险,尽管更常达到足够的C。通过剂量调整进行TDM可改善AMK治疗,但仍需进一步研究。